Neuroendocrine tumors are rare, accounting for less than 1% of all malignant tumors, and most of them occur in the stomach, intestines, and pancreas. The most common type of cancer in this type of tumor is carcinoid, with an incidence of about 2.5/100000, accounting for 50% of all gastrointestinal pancreatic neuroendocrine tumors. Carcinoid tumors can be divided into anterior intestine (lung, lung, Bronchus and upper gastrointestinal tract up to jejunum), midgut (ileum and appendix) and hindgut (rectum and rectum). Such tumors can occur in the entire neuroendocrine system, but the most common site of involvement is the pancreas. Neuroendocrine tumors can be divided into two major categories according to whether the substances secreted by the tumo cause typical clinical symptoms mdash; mdash; functional and non-functional.
A halin yanzu, magani mafi inganci don ciwan ciwan neuroendocrine a duniya shine peptide receptor radionuclide therapy (PRRT). Mai zuwa labarin ne da wani likita Ba'amurke ya rubuta akan peptide receptor radionuclide therapy:
Mene ne mai karɓar maganin peptide Radionuclide far (PRRT)?
Menene peptide receptor radionuclide therapy (PRRT) kuma yaya yake aiki?
Peptide receptor radionuclide therapy (PRRT) magani ne mai alaƙa da ƙwayoyin cuta (wanda kuma ake kira radioisotope far) da ake amfani da shi don magance takamaiman nau'in cutar kansa, da ake kira munanan cututtukan neuroendocrine ko ciwukan Neuroendocrine (ƙwayoyin neuroendocrine). Peptide receptor radionuclide far (PRRT) kuma ana nazarinsa azaman magani don ƙwanƙwarar prostate da pancreatic.
A cikin peptide receptor radionuclide therapy (PRRT), furotin (ko peptide) da ake kira tantanin halitta wanda ake kira octreotide, haɗe tare da ƙaramin adadin kayan aikin rediyo, ko radionuclide, yana samar da nau'in radiopharmaceutical na musamman da ake kira peptide radioactive. Lokacin da aka yi masa allura a cikin jinin majiyyaci, wannan aikin rediyo yana shiga kuma yana haɗuwa da ƙwayoyin tumor neuroendocrine, yana ba da babban maganin rediyo ga ciwon daji.
A mafi yawan kwayoyin cututtukan neuroendocrine, wadatarwa (wanda ake kira overexpression) yana da adadi na musamman na nau'ikan masu karɓar farfajiya - ana rarraba wannan furotin akan kwayar halitta - ana kiran hormone da ke haɗe da jiki girma. Octreotide wani hormone ne wanda aka haɗu a cikin dakin gwaje-gwaje, wanda ke haɗe da ƙwayar haɓakar haɓakar haɓakar haɓakar ƙwayar cuta ta neuroendocrine. A cikin peptide receptor radionucliderapy (PRRT), octreotide haɗe tare da allurai masu warkewa na radionuclide yttrium-90 (Y-90) da lutetium 177 (Lu-177) shine mafi yawan amfani da radionuclide.
Waɗanne cututtuka ne za a iya magance su ta hanyar maganin maganin radionuclide na rashi (PRRT)?
Is peptide receptor radionuclide therapy ( PRRT) used to treat neuroendocrine tumors? (NETs), including carcinoid ciwace -ciwacen daji, pancreatic islet cell carcinoma, small cell lung cancer, pheochromocytoma (a rare tumor formed in the adrenal glands), stomach-intestine-pancreas (stomach, intestine and pancreas) neuroendocrine tumors, And rare thyroid cancer that does not respond to radioactive iodine therapy.
Peptide receptor radionuclide far (PRRT) zaɓi ne ga marasa lafiya:
• Mai haƙuri ya ci gaba da / ko ciwan ciwan neuroendocrine
• Marasa lafiya wadanda basu dace da tiyata ba
• Alamar mara lafiyar ba ta amsa wasu magunguna
Babban makasudin maganin peptide receptor radionucliderapy (PRRT) shine don taimakawa sauƙaƙe bayyanar cututtuka, dakatar ko jinkirta ci gaban tumo da inganta rayuwa gabaɗaya.
Ta yaya peptide receptor radionuclide therapy (PRRT) ke aiki?
Dangane da nau'in cutar kansa da ake kula da ita da kayan aikin jiyya da ke aiwatar da aikin jiyya, marasa lafiya za su iya karɓar hawan keke na 10 na Peptide receptor radionuclide far (PRRT), an raba su cikin watanni 2-3. Dangane da maganin radionuclide da ake aiwatarwa da ƙa'idodin ƙa'idar gida, ana iya amfani da wannan hanyar azaman aikin jiyya na marasa lafiya, ko yana iya buƙatar 'yan kwanaki na jinyar asibiti.
Kowane Peptide receptor radionuclide far (PRRT) yana farawa lokacin da amino acid ke cikin allurar cikin sauƙi don kare kodar mara lafiya daga radiation. Daga baya an yi allurar peptide na rediyo a cikin mai haƙuri, sannan ƙarin bayani na amino acid ya biyo baya. Gaba ɗaya, tsawon lokacin magani ya kusan kusan awanni 4.
Yayin jinya na gaba, ana iya yin sikanin hoton kwayoyin don lura da inda peptide mai tasirin iska ya shiga jiki, kodayake wadannan ba tilas bane.
Menene fa'idodin maganin peptide receptor radionuclide therapy (PRRT)?
Peptide receptor radionuclide therapy (PRRT) da sauran hanyoyin kwantar da hankali na ƙwayoyin cuta na iya ba da ƙarin jiyya na cutar kansa saboda ana iya daidaita magungunan rediyo bisa ga halaye na halitta na musamman na mai haƙuri da halayen ƙwayoyin ƙwayar cuta. Peptide receptor radionuclide therapy (PRRT) shima ana ɗaukarsa azaman magani ne da aka yi niyya, saboda peptides na rediyo yana da ikon da za su lalata ƙwayoyin tumor neuroendocrine sosai, yayin da suke iyakance bayyanar nama na yau da kullun zuwa radiation. Sabili da haka, gabaɗaya, peptide receptor radionuclide far (PRRT) yana da ɗan ƙaramin sakamako masu illa idan aka kwatanta da chemotherapy.
Peptide receptor radionuclide far (PRRT) wani nau'in ne wanda ke da babban tasiri na zaɓuɓɓukan magani don sarrafa ƙwayar cutar neuroendocrine na ci gaba, mai ci gaba. Peptide receptor radionuclide far (PRRT) ba magani ne na warkewa ba, amma an nuna yana taimakawa rage alamun cutar da jinkirta ci gaban cuta.
Shin peptide receptor radionuclide therapy (PRRT) lafiya ne?
Dukkanin jiyya, gami da maganin peptide receptor radionuclide therapy (PRRT), suna da illoli da haɗari. Ya kamata ku tattauna haɗari da fa'idar peptide receptor radionucliderapy (PRRT) tare da mai ba ku magani, da kuma duk wasu jiyya da kuke la'akari. Dangane da tarihin lafiyar ku, mai ba ku magani zai taimaka muku yanke shawara ko peptide receptor radionuclide therapy (PRRT) shine zaɓinku mafi dacewa. Tabbatar da sanar da mai ba da magani game da duk wani magani da aka riga aka samu, saboda wannan yana taka muhimmiyar rawa wajen daidaita ƙayyadadden magani da sashin magani.
Hanyoyi masu illa na maganin karbawar peptide radionuclide therapy (PRRT)?
Peptide receptor radionuclide therapy (PRRT) da kanta an yarda da shi sosai, amma a lokacin infusions amino acid, marasa lafiya galibi suna yin tashin zuciya da amai (wani lokacin ma mai tsanani). Wannan yana buƙatar maganin rigakafin tashin zuciya ko rage jinkirin gudanar da amino acid. A cikin dogon lokaci, illa masu illa za su haɗa da ƙididdigar jini akai -akai. Gabaɗaya, yawancin marasa lafiya suna jure wannan magani.
Kulawar gida
Gidan likitan ku zai ba ku jagora don magani na gaba. Saboda karamin maganin rediyo na iya zama a cikin jiki, marasa lafiya suna buƙatar shan wani magani bayan kwanaki 1-2 bayan sun sami maganin peptide receptor radionuclide therapy (PRRT). Saboda ragowar radionuclides ana share su daga jiki ta hanyar fitsari da najasa, yana da mahimmanci a kula da tsaftar bandaki a wannan lokacin.
Menene sabon ci gaba a cikin binciken peptide receptor radionuclide far (PRRT)?
Peptide receptor radionuclide therapy (PRRT) bincike yanzu an mayar da hankali kan kammala kashi na III gwaje-gwaje na asibiti, kuma yana fatan samun amincewar FDA ta Amurka don alamun sa jim kaɗan bayan haka. Bincike mai gudana kuma ya haɗa da bincike akan waɗannan aikace-aikacen:
• Yi amfani da peptides guda biyu tare
• An haɗa peptides na rediyo tare da wasu jiyya na jiyya
• Maimaita aikace -aikacen aikin rediyo
• Ƙara yawan alamun wannan nau'in maganin radiation, ciki har da sauran cututtuka
• Sauran amfani haɗin haɗin radionuclide-peptide.
